EndoscopyJournal Article
08 Jul 2025
Endoscopic bariatric and metabolic therapies (EBMTs) are increasingly recognized as valuable tools for managing obesity and related metabolic disorders. As the prevalence of obesity continues to rise globally, there is a growing demand for effective, safe, and less invasive treatment options.
This review provides a comprehensive summary of the available EBMTs, including both stomach-targeted and small-bowel-targeted devices. The review details the various devices, outlines the techniques for their proper use, and discusses their indications.
It also presents data on their efficacy and safety, and the management of adverse events and weight regain, as well as anticipated future developments.
The paper emphasizes the necessity for additional high quality randomized controlled trials and long-term outcome data to better define the role of these therapies within obesity treatment protocols.
Overall, this review serves as an authoritative resource for endoscopists, bariatric specialists, and the wider healthcare community involved in obesity care, promoting best practices and guiding the appropriate implementation of EBMTs in clinical settings.
B. Abu Dayyeh has received consultancy fees and research support from Endogastric Solutions (2017 to present), consultancy fees from Boston Scientific (2018 to present), Medtronic (2019 to present), and Olympus (2020 to present), and research support from Apollo Endosurgery (2012 to 2022), USGI Medical (2018 to present), and Spatz Medical (2015 to 2020); he is a co-inventor of Endogenex, a technology that is licensed through a Mayo Clinic licensing agreement and in which he co-invested. I. Boškoski has provided consultancy to Apollo Endosurgery and Boston Scientific, Nitinotes, and EndoTools Therapeutics (all 2023 to 2024). V. Huberty is a shareholder and board member of EndoTools Therapeutics (2011 to present), a board member of Ambu (2023 to present), and has provided consultancy to Boston Scientific (2022 to present). R. Maselli has provided consultancy to Boston Scientific (2019 to present). S. Shamah has received consultancy fees from Nitinotes Endoscopy (2021 to present) and educational fees for Apollo Endosurgery (2020 to present). R.Z. Sharaiha has received consultancy fees and research support from Boston Scientific (2017 to present), consultancy fees from Surgical Intuitive (2021 to present), and research support from Olympus/Cook (2019 to 2022). C. Stier has received consultancy fees from Boston Scientific and USGI (both 2023 to present). V. Bove, M. De Siena, A. Facciorusso, L. Fuccio, M.V. Matteo, S. Perretta, and V. Pontecorvi declare that they have no conflicts of interest.
Share: